Blueprint Medicines Corporation (NASDAQ:BPMC)‘s stock had its “buy” rating reissued by investment analysts at Cowen and Company in a research note issued on Friday.

The analysts wrote, “We maintain our BUY rating following the Q3/17 results. Histogenics reported zero revenue and a diluted net loss of $5.1M, compared to CG/ consensus of $6.5M/$6.3M net loss, and LPS of $(0.23), compared with CG/consensus estimate of $(0.29)/$(0.28). As anticipated, the Q3 call was largely uneventful as Histogenics awaits one-year data from the NeoCart Phase 3 clinical trial. Management noted that 65% of patients are now at the one-year mark and reiterated their expectation for one-year data to be announced in Q3/18.””

Other equities analysts have also recently issued reports about the stock. DA Davidson started coverage on shares of Blueprint Medicines Corporation in a research note on Friday, September 29th. They issued a “buy” rating and a $90.00 price objective on the stock. BTIG Research started coverage on shares of Blueprint Medicines Corporation in a research report on Friday, September 29th. They set a “buy” rating and a $90.00 price target on the stock. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $79.00 price target (up from $64.00) on shares of Blueprint Medicines Corporation in a research report on Wednesday, September 20th. Canaccord Genuity lifted their price target on shares of Blueprint Medicines Corporation from $56.00 to $66.00 and gave the stock a “buy” rating in a research report on Wednesday, September 20th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $56.00 price target on shares of Blueprint Medicines Corporation in a research report on Tuesday, September 5th. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $70.47.

Shares of Blueprint Medicines Corporation (NASDAQ:BPMC) traded down $1.90 during mid-day trading on Friday, reaching $68.32. 265,885 shares of the company’s stock were exchanged, compared to its average volume of 367,402. Blueprint Medicines Corporation has a 1 year low of $25.08 and a 1 year high of $74.42. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.02.

Blueprint Medicines Corporation (NASDAQ:BPMC) last announced its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.06). Blueprint Medicines Corporation had a negative net margin of 437.83% and a negative return on equity of 43.11%. The business had revenue of $8.07 million during the quarter, compared to the consensus estimate of $5.35 million. During the same period in the previous year, the business posted ($0.62) earnings per share. Blueprint Medicines Corporation’s revenue was up 31.0% compared to the same quarter last year. equities analysts anticipate that Blueprint Medicines Corporation will post -3.74 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/11/10/cowen-and-company-reiterates-buy-rating-for-blueprint-medicines-corporation-bpmc.html.

In other news, Director Daniel Lynch sold 2,500 shares of the business’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $60.00, for a total transaction of $150,000.00. Following the transaction, the director now directly owns 209,342 shares in the company, valued at approximately $12,560,520. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kate Haviland sold 6,356 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $60.03, for a total transaction of $381,550.68. Following the transaction, the insider now owns 6,356 shares in the company, valued at $381,550.68. The disclosure for this sale can be found here. Insiders have sold a total of 49,305 shares of company stock worth $3,354,882 over the last 90 days. 3.40% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rockefeller Financial Services Inc. acquired a new position in Blueprint Medicines Corporation in the 3rd quarter valued at about $160,000. Ameritas Investment Partners Inc. grew its stake in Blueprint Medicines Corporation by 68.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 1,391 shares during the last quarter. UBS Asset Management Americas Inc. acquired a new position in Blueprint Medicines Corporation in the 1st quarter valued at about $201,000. Fred Alger Management Inc. acquired a new position in Blueprint Medicines Corporation in the 2nd quarter valued at about $203,000. Finally, SG Americas Securities LLC grew its stake in Blueprint Medicines Corporation by 23.3% in the 2nd quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 778 shares during the last quarter. Institutional investors and hedge funds own 90.79% of the company’s stock.

Blueprint Medicines Corporation Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Analyst Recommendations for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.